LXRX — Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc (LXRX) is a biotechnology company listed on NASDAQ. It is led by Michael S. Exton Ph.D., based in 2445 Technology Forest Boulevard, The Woodlands, TX, United States, 77381, with about 103 employees. Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Latest reported LXRX revenue for 2025-09-30 was $14.2M. Net income was -$12.8M. Revenue was down 50.9% from 2025-06-30 to 2025-09-30. LXRX currently screens at market cap $327.2M.

Use this LXRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the LXRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the LXRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Lexicon Pharmaceuticals Inc even when a live quote feed is slow.